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This retrospective analysis examines the local control and toxicity of ﬁve-fraction ﬁducial-
free CyberKnife stereotactic body radiation therapy (SBRT) for single vertebral body (VB)
metastases. All patients had favorable performance status (ECOG 0–1), oligometastatic
disease, and no prior spine irradiation. A prescribed dose of 30–35 Gy was delivered in
ﬁve fractions to the planning target volume (PTV) using the CyberKnife with X-sight spine
tracking. Suggested maximum spinal cord and esophagus point doses were 30 and 40 Gy,
respectively. A median 30 Gy (IQR, 30–35 Gy) dose was delivered to a median prescription
isodose line of 70% (IQR, 65–77%) to 20 patients. At 34 months median follow-up (IQR,
25–40 months) for surviving patients, the 1- and 2-year Kaplan–Meier local control esti-
mates were 80 and 73%, respectively. Two of the ﬁve local failures were inﬁeld in patients
who had received irradiation to the gross tumor volume and three were paravertebral fail-
ures just outside the PTV in patients with prior corpectomy. No local failures occurred
in patients who completed VB radiation alone. The 1- and 2-year Kaplan–Meier over-
all survival estimates were 80 and 57%, respectively. Most deaths were attributed to
metastatic disease; one death was attributed to local recurrence. The mean maximum
point doses were 26.4 Gy (SD, 5.1 Gy) to the spinal cord and 29.1 Gy (SD, 8.9 Gy) to the
esophagus. Patients receiving maximum esophagus point doses greater than 35 Gy expe-
rienced acute dysphagia (Grade I/II). No spinal cord toxicity was documented. Five-fraction
ﬁducial-free CyberKnife SBRT is an acceptable treatment option for newly diagnosed VB
metastases with promising local control rates and minimal toxicity despite the close prox-
imity of such tumors to the spinal cord and esophagus. A prospective study aimed at
further enhancing local control by targeting the intact VB and escalating the total dose is
planned.
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INTRODUCTION
Annually, 5–10% of patients with systemic cancer will develop
symptomatic spine metastases (Ries et al., 2008). Patients with
common malignancies such as breast, prostate, and lung cancer
develop spine metastases at higher rates. The management of
vertebral body (VB) metastases varies depending on an indi-
vidual’s prognosis and the involved spine’s structural integrity.
Patients carrying a poor prognosis without evidence of bony
retropulsion into the anterior epidural space or spinal instability
have traditionally received conventional radiation therapy alone
withmoderate success (Faul andFlickinger, 1995). Despite provid-
ing excellent early palliation of symptoms, conventional radiation
has resulted in poor local control rates with one major survey
placing the crude, overall local control rate at 77%, and another
large Phase III study estimating a median time to recurrence of
5 months (Maranzano and Latini, 1995; Moulding et al., 2010).
Patients remain at signiﬁcant risk of developing debilitating spine
progression following conventional irradiation (Ryu et al., 2007;
Gibbs et al., 2009).
In an effort to enhance local control and minimize radia-
tion toxicity researchers in the past decade have explored various
means of improving spine irradiation. This research has resulted
in a new treatment paradigm, stereotactic body radiation therapy
(SBRT). With improved dose distributions and accuracy, SBRT
has facilitated the safe painless delivery of high doses of radi-
ation quickly to localized spine tumors. Multiple studies have
conﬁrmed the efﬁcacy of SBRT with early symptomatic improve-
ment seen in 86–96% of treated patients following delivery of one
to ﬁve fractions (Gerszten et al., 2004, 2007; Ryu et al., 2004, 2008;
Degen et al., 2005; Yamada et al., 2005, 2008; Chang et al., 2007;
Gibbs et al., 2007; Gagnon et al., 2009). Despite growing evidence
supporting SBRT in poor prognosis, previously irradiated spine
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metastases patients, few studies have established local control rates
for newly diagnosed relatively good prognosis patients with single
VB metastases.
The CyberKnife System (Accuray Incorporated, Sunnyvale,
CA, USA) has been successfully employed at Georgetown Univer-
sity Hospital since early 2002 to treat spine tumors with ﬁducial
tracking. Institutional reports have documented this technology’s
ability to reliably palliate tumor induced spine pain with poten-
tially safer fractionated radiationdoses (Degen et al., 2005; Gagnon
et al., 2009). The accuracy andﬂexibility of theﬁducial-free system,
X-sight spine tracking, prompted us in late 2005 to evaluate a ﬁve-
fraction CyberKnife SBRT treatment for good prognosis patients
with single VB metastases that were not previously irradiated
(Muacevic et al., 2006; Ho et al., 2007). The system’s unique con-
ﬁguration facilitates the accurate delivery of fractionated high dose
radiation, despite the close proximity of such tumors to radiation
sensitive structures such as the spinal cord and esophagus (Kilby
et al., 2010). We report outcomes for 20 consecutively treated, eli-
gible patients with newly diagnosed single VB metastases treated
using this novel treatment approach.
MATERIALS AND METHODS
ELIGIBILITY
This retrospective analysis of an established departmental treat-
ment approach was approved by the MedStar Health Research
Institute – Georgetown University Oncology Institutional Review
Board. Consecutive patients with good prognosis singleVBmetas-
tases treated with ﬁve-fraction ﬁducial-free CyberKnife SBRT
between September 2005 and September 2010 were analyzed.
Patients were considered to have a good prognosis if they had
a favorable performance status (ECOG 0–1) and oligometastatic
disease. A tumor was considered a single VB metastasis if it pri-
marily involved a single VB. Patients with previously irradiated
spine or uncorrected spinal cord compression were excluded from
analysis.
TREATMENT PLANNING AND DELIVERY
A ﬁne-cut (1.25 mm) contrast enhanced treatment planning CT
scan was obtained in the supine treatment position for each
patient. Oral contrast was routinely used to delineate the esoph-
agus. CT myelogram was used to deﬁne the spinal cord when
clinically indicated. The planning target volume (PTV), either the
gross tumor volume (GTV), or the involved VB, was contoured at
the discretion of the treating physician. A treatment plan was gen-
erated using the MultiPlan 5.2.1 non-isocentric, inverse-planning
algorithm with tissue density heterogeneity corrections for lung
based on an effective depth correction. The radiation dose was
divided into ﬁve equal fractions of 6–7 Gy, prescribed to an iso-
dose line that covered at least 80% of the PTV. Guidelines for
dose limits to critical structures are provided in Table 1. Patients
were treated in the supine position as previously described using
ﬁducial-free CyberKnife spine tracking (Muacevic et al., 2006; Ho
et al., 2007).
FOLLOW-UP
Patients were followed with physical examination plus MRI
and/or PET/CT imaging at 3- to 6-month intervals per routine
Table 1 | Institutional maximum point dose limit guidelines for
adjacent critical structures.
Adjacent critical structure Maximum point dose limit
(Gy; total for five fractions)
Spinal cord 30
Nerve roots 35
Esophagus 40
Bowel 40
institutional practice. Local tumor recurrence was deﬁned as
progression of the treated tumor per selected imaging. Biopsies
were obtained when clinically indicated. Toxicities were scored
according to the National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events, Version 3.0 (National Institutes of
Health, 2006).
STATISTICAL ANALYSIS
Statistical analysis was performed with the SPSS 17 (IBM Cor-
poration, Armonk, NY, USA) statistical software package. The
follow-up duration was deﬁned as the time from the date of treat-
ment completion to the last date of follow-up or the date of death.
Actuarial local control and overall survival were calculated using
the Kaplan–Meier method. For the sake of robustness, all reported
ranges are interquartile (IQR, Q1–Q3).
RESULTS
PATIENT CHARACTERISTICS
Twenty consecutive patients, 6 men and 14 women, were treated
over a 60-month period and followed for aminimumof 12months
oruntil death (Table 2). Primary cancers included sarcoma (n=7),
breast cancer (n= 5), non-small cell lung cancer (n= 2), prostate
cancer (n= 1), clear cell renal cancer (n= 1), papillary thyroid can-
cer (n= 1), melanoma (n= 1), plasmacytoma (n= 1), and acinic
cell salivary gland cancer (n = 1). All patients were chemother-
apy candidates; 30% required corpectomy prior to CyberKnife
treatment.
TREATMENT CHARACTERISTICS
Treatment plans were composed of hundreds of pencil beams
delivered using a single 10–35 mm diameter collimator (median,
20 mm). The majority of patients (60%) received VB irradi-
ation; the remainder had the GTV alone targeted. The mean
PTV was 121 cc (SD, 116 cc). Radiation was delivered in ﬁve
equal fractions of 6–7 Gy over a median of 7 days (IQR, 5–
9 days). The median prescription isodose line was 70% (IQR,
65–77%), the median dose was 30 Gy (IQR, 30–35 Gy) and the
median PTV coverage was 95% (IQR, 87–97%). The resulting
mean maximum point doses delivered to the spinal cord and
esophagus were 26.4 Gy (SD, 5.1 Gy) and 29.1 Gy (SD, 8.9 Gy),
respectively.
LOCAL CONTROL AND SURVIVAL
Local control and survival outcomes were favorable (Figure 1;
Table 3). At a median follow-up of 34 months for surviving
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Table 2 | Treatment characteristics.
Patient Histology Level Surgery PTV (cc) Prescription dose (Gy) Target
1 Sarcoma (MFH) T5 Y 51 35 VB
2 Breast L4 N 89 30 VB
3 Sarcoma (leiomyosarcoma) S2 Y 181 35 GTV
4 Breast T9 N 42 30 VB
5 Breast T7 N 19 30 VB
6 Lung (NSCLC) T9 N 91 30 GTV
7 Thyroid T10 N 23 35 GTV
8 Prostate T12 N 99 35 VB
9 Sarcoma (liposarcoma) L1 N 12 35 GTV
10 Melanoma L4 Y 292 30 VB
11 Sarcoma (leiomyosarcoma) L3 Y 150 35 VB
12 Sarcoma (osteosarcoma) C6 N 13 35 VB
13 Renal T8 N 3 30 VB
14 Plasmacytoma T7 N 20 30 GTV
15 Breast L1 N 81 30 VB
16 Breast L1 N 114 30 VB
17 Sarcoma (rhabdomyosarcoma) T11 Y 350 30 GTV
18 Salivary gland (acinic) S3 N 324 35 GTV
19 Lung (NSCLC) T2 N 336 30 GTV
20 Sarcoma (giant cell) T1 Y 124 35 VB
GTV, gross tumor volume; NSCLC, non-small cell lung cancer; MFH, malignant ﬁbrous histiocytoma; VB, vertebral body.
FIGURE 1 | Osteosarcoma C6 oligometastasis PET/CT scan with a tumor SUVmax of 11 (A); (B) CyberKnife treatment plan showing the vertebral body planning
treatment volume in yellow and the 35 Gy isodose line in blue; and (C) PET/CT scan at 3 years post-treatment shows a durable complete response with a tumor
SUVmax of 1.7.
patients, the 1- and 2-year Kaplan–Meier local control estimates
were 80 and 73%, respectively (Figure 2). Of the ﬁve observed local
failures, twowere inﬁeld local failures in patients who had received
irradiation to the GTV alone and three were paravertebral fail-
ures just outside the PTV in patients requiring corpectomy prior
to treatment. Four of the seven treated sarcomas failed locally.
No local failures were identiﬁed beyond 14 months or in patients
who completed VB irradiation alone. The 1- and 2-year Kaplan–
Meier overall survival estimates were relatively favorable at 80
and 57%, respectively (Figure 3). Nine deaths were attributed
to metastatic disease; one death was attributed to local recurrence
(Figure 4).
COMPLICATIONS
Conservative maximum point dose guidelines for normal tissues
were generally observed. Patients receiving maximum esophageal
point doses greater than 35 Gy (n= 4) experienced acute dyspha-
gia/esophagitis (Grade I/II) lasting several weeks. No skin, mus-
culoskeletal or neurologic toxicities were attributed to CyberKnife
treatment.
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Table 3 | Clinical outcomes.
Patient Local failure Vital status Survival Cause of death
(month) (month)
1 7 Dead 36 Metastases
2 – Dead 27 Metastases
3 – Dead 20 Metastases
4 – Dead 18 Metastases
5 – Dead 12 Metastases
6 5 Dead 12 Metastases
7 – Alive 63 –
8 – Alive 50 –
9 14 Dead 24 Local failure
10 – Alive 40 –
11 12 Alive 40 –
12 – Alive 39 –
13 – Dead 14 Metastases
14 – Alive 28 –
15 – Alive 25 –
16 – Alive 25 –
17 6 Dead 10 Metastases
18 – Alive 14 –
19 – Dead 6 Metastases
20 – Alive 12 –
DISCUSSION
The CyberKnife’s image guidance system uniquely facilitates both
extreme accuracy (<1 mm) and fractionation (Kilby et al., 2010).
In our opinion, both capabilities are necessary to optimally treat
tumors in close proximity to the spinal cord. Georgetown Univer-
sityHospital researchers have documented theCyberKnife’s ability
to reliably palliate tumor induced spine pain with potentially
safer fractionated radiation doses using ﬁducial tracking (Degen
et al., 2005; Gagnon et al., 2009). However, the required ﬁducial
placement uniformly necessitated a delay in treatment and was a
potentially hazardous invasive procedure that concerned potential
users. In 2005 the CyberKnife image guidance system was recon-
ﬁgured to track the spine itself (Muacevic et al., 2006; Ho et al.,
2007). This development led to the broad adoption of CyberKnife
spine SBRT.
With the introduction of ﬁducial-free CyberKnife spine tech-
nology to Georgetown University Hospital in 2005, we instituted
a ﬁve-fraction treatment approach for newly diagnosed single VB
oligometastases. This fractionation schedule was selected to opti-
mize local control and normal tissue radiation tolerance in this
groupof patientswith expected favorable survival. Twenty patients
were treated in 60 months and followed for a minimum of 1 year.
At a median follow-up of 34 months for surviving patients, the 1-
and 2-year Kaplan–Meier local control estimates are 80 and 73%,
respectively. This is somewhat lower than the typical 90% local
control rates reported by prior institutional series (Gerszten et al.,
2009). Although this small decrement in local control is likely
FIGURE 2 | Kaplan–Meier plot of local control.
FIGURE 3 | Kaplan–Meier plot of overall survival.
the result of the improved survival seen in this cohort, several
minor adjustments to our approach have been made in an effort
to improve this outcome.
Prior to proceeding with our ﬁve-fraction ﬁducial-free
CyberKnife approach for single VB metastases there was no stan-
dard PTV for spine SBRT. Therefore, we left it to the treating
physician to determine whether they would target the GTV or the
VB itself. The majority of physicians (60%) chose to treat the VB
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FIGURE 4 | (A) Solitary L1 liposarcoma metastasis; (B) CyberKnife treatment plan dose distribution with gross tumor volume shown in red and the 35 Gy isodose
line in blue; and (C) MRI at 14 months post-treatment with local recurrence.
in order to addressmicroscopic disease spread within theVB itself.
Two local failures in this study were attributed to irradiation of
only the GTV; future patients will receive VB irradiation only.
The remaining three local failures were paravertebral failures
just outside the PTV in patients with advanced spine metastases
requiring corpectomy. The local failure rate for postoperative
patients in this study was 50%. Therefore, we have decided to
exclude such patients from this approach in the future; it is
our opinion that good prognosis patients with likely intraoper-
ative microscopic disease spread would be better treated with a
combination of conventional radiation and CyberKnife as a boost.
Finally, it is likely that good prognosis patients with single
VB metastases would beneﬁt from dose escalation (Yamada et al.,
2008). The ﬁve local failures observed in this study were seen in
patients with tumors that were generally considered radioresistant
(Tables 2 and 3; Gerszten et al., 2009). Furthermore, meaning-
ful toxicity was observed only in patients receiving maximum
esophagus point doses greater than 35 Gy. A planned institutional
dose escalation study will gradually raise the current typically dose
limiting maximum spinal cord point dose from 30 to 35 Gy as
tolerated. The current esophagus maximum point dose will be
decreased to 35 Gy to minimize acute dysphagia.
CONCLUSION
Five-fraction ﬁducial-free CyberKnife SBRT is a promising treat-
ment option for VB tumors, demonstrating encouraging local
control rates with nominal toxicity despite the close proximity
of such tumors to the spinal cord and esophagus. A prospective
dose escalation study targeting the intact VB is planned to further
enhance local control in this patient population.
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